AdAlta Focuses on CAR-T Licensing and Strategic Options in March 2025 Quarter

AdAlta Limited (ASX: 1AD) reported a mixed March 2025 quarter, marked by strategic progress in its cellular immunotherapy program and a challenging funding environment. The Company prioritized its “East to West” CAR-T strategy as the core growth pillar. It reaffirmed that further advancement of its antifibrotic lead asset, AD-214, will occur only via third-party partnerships.

Key achievements included executing three CAR-T term sheets, substantially completing technical due diligence, and a first licensing agreement targeted for the June quarter of 2025. Additionally, AdAlta signed a Heads of Agreement with SYNthesis BioVentures (SYNBV) for up to AU$2 million in seed funding for its CAR-T subsidiary, AdCella Pty Ltd. However, investment conditions remain unmet due to volatile market conditions. In response, AdAlta has ceased internal discovery R&D, implemented cash-saving measures, and engaged capital advisors to explore financing and strategic alternatives. The Company also received its first partnering inquiry for its anti-malarial i-body candidate, WD-34.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com